Abstract
We present a systematic assessment of polygenic risk score (PRS) prediction across more than 1,600 traits using genetic and phenotype data in the UK Biobank. We report 428 sparse PRS models with significant (p < 2.5 × 10−5) incremental predictive performance when compared against the covariate-only model that considers age, sex, and the genotype principal components. We report a significant correlation between the number of genetic variants selected in the sparse PRS model and the incremental predictive performance in quantitative traits (Spearman’s ρ = 0.54, p = 1.4 × 10−15), but not in binary traits (ρ = 0.059, p = 0.35). The sparse PRS model trained on European individuals showed limited transferability when evaluated on individuals from non-European individuals in the UK Biobank. We provide the PRS model weights on the Global Biobank Engine (https://biobankengine.stanford.edu/prs).
Competing Interest Statement
M.A.R is on the SAB of 54Gene and Computational Advisory Board for Goldfinch Bio and has advised BioMarin, Third Rock Ventures, MazeTx, and Related Sciences.
Funding Statement
This work has been supported by the Funai Foundation for Information Technology [to Y.T.]; Stanford University School of Medicine [to R.L.; Y.T.; and M.A.R.]; National Institute of Health center for Multi and Trans-ethnic Mapping of Mendelian and Complex Diseases [5U01 HG009080 to M.A.R]; National Human Genome Research Institute of the National Institutes of Health [R01HG010140 to M.A.R.]; National Institute of Health [5R01 EB001988-16 to R.T., 5R01 EB 001988-21 to T.H.]; and National Science Foundation [19 DMS1208164 to R.T., DMS-1407548 to T.H.].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Based on the information provided in Protocol 44532, the Stanford IRB has determined that the research does not involve human subjects as defined in 45 CFR 46.102(f) or 21 CFR 50.3(g).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The sparse PRS model weights generated from this study are available on the Global Biobank Engine (https://biobankengine.stanford.edu/prs).
